posted on 2022-03-17, 20:14authored byChih-Jung Chen, Chen Jiang, Jiayi Yuan, Maozi Chen, Jacob Cuyler, Xiang-Qun Xie, Zhiwei Feng
Allosteric modulators (AMs) that bind allosteric sites can exhibit greater
selectivity than
the orthosteric ligands and can either enhance agonist-induced receptor
activity (termed positive allosteric modulator or PAM), inhibit agonist-induced
activity (negative AM or NAM), or have no effect on activity (silent
AM or SAM). Until now, it is not clear what the exact effects of AMs
are on the orthosteric active site or the allosteric binding pocket(s).
In the present work, we collected both the three-dimensional (3D)
structures of receptor–orthosteric ligand and receptor–orthosteric
ligand–AM complexes of a specific target protein. Using our
novel algorithm toolset, molecular complex characterizing system (MCCS),
we were able to quantify the key residues in both the orthosteric
and allosteric binding sites along with potential changes of the binding
pockets. After analyzing 21 pairs of 3D crystal or cryo-electron microscopy
(cryo-EM) complexes, including 4 pairs of GPCRs, 5 pairs of ion channels,
11 pairs of enzymes, and 1 pair of transcription factors, we found
that the binding of AMs had little impact on both the orthosteric
and allosteric binding pockets. In return, given the accurately predicted
allosteric binding pocket(s) of a drug target of medicinal interest,
we can confidently conduct the virtual screening or lead optimization
without concern that the huge conformational change of the pocket
could lead to the low accuracy of virtual screening.